{"schema_version":"1.0","type":"article","title":"年營收 92 億美元，強生為什麼還想把骨科拆出去？","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.md","lang":"zh-Hant","date":"2026-09-28","publish_at":"2026-09-28T08:00:00+08:00","updated_at":"2026-09-28","category":"商業分析系列","topic":"商業分析系列","tags":["強生","DePuy Synthes","骨科","業務分離","Apollo","聯合骨科"],"summary":"一年銷售92億美元的骨科業務，為何仍可能排不到強生下一筆資金？從成長差異、分拆與出售的價值流向，到人工關節與手術支援的經營成本，拆解DePuy Synthes分離案真正要算的帳。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"強生與擬獨立DePuy Synthes的策略分工；計畫尚未完成，成長與利潤率改善屬公司預期。","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation/01_%E5%88%86%E9%9B%A2%E7%AD%96%E7%95%A5_ZH_v2.png"},{"alt":"兩條示意路徑：股權分派式分拆與對外出售；股份、業務權利與對價分別流向不同對象。","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation/02_%E5%88%86%E9%9B%A2%E9%80%94%E5%BE%91_ZH_v2.png"},{"alt":"媒體洽談、正式契約、完成公告三種證據層級；200億美元是匿名報導所述估值。","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation/03_%E6%B4%BD%E8%AB%87%E8%AD%89%E6%93%9A_ZH_v1.png"},{"alt":"聯合骨科的植入物、器械與製造能力，與尚缺直接證據的交易關係、訂單及財務受益分開。","url":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation/04_%E5%8F%B0%E7%81%A3%E8%83%BD%E5%8A%9B_ZH_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/jnj-orthopaedics-separation/01_%E5%88%86%E9%9B%A2%E7%AD%96%E7%95%A5_ZH_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-28）。年營收 92 億美元，強生為什麼還想把骨科拆出去？。https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-28-jnj-orthopaedics-separation-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}